Ovarian CancerNCT04170712
Data and Specimen Bank of Patients Diagnosed With, and at High-risk for, Gynecologic Cancers
An observational study of Ovarian Cancer, run by University of Virginia at 1 site in United States.
Trial summary
The purpose of this project is to establish a bank at UVa of tampon samples, cervical swabs, blood, associated tumor specimens that would otherwise be discarded, and relevant medical data from consenting patients that have suspected and/or confirmed gynecological cancer diagnoses. Read more about this study
- Who is it for?
- Ages 18 years and older, women onlyHealthy volunteers can take part
- Conditions the study is for
- Ovarian Cancer
- What is being tested?
- Tampons
- How many people
- 400 participants
- Where
- 1 siteUnited States
- Study dates
- 10 Jun 2016to 10 Jun 2022
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- Women only
- Healthy volunteers accepted
- Adult, Older adult
Study population: Patients with confirmed ovarian cancer diagnosis or suspicious mass or patients with a strong family history of ovarian cancer or genetic mutation that puts them at high risk for ovarian cancer
Who may be able to join
- Adult female non-pregnant patients with high risk for gynecological and/or breast cancer who will be:
- undergoing a planned surgery with the UVa Department of gynecological oncology for gynecological, breast, and/or related cancers and conditions
- undergoing surveillance in the high-risk gynecological oncology clinic for gynecological, breast, and/or related cancers and conditions
Who cannot join
- • Is under the age of 18
- is pregnant
Trial locations and contacts
1 site in 1 country.
United States1 site, 1 recruiting
- Recruiting
University of Virginia
Charlottesville, Virginia, 22908
Rachel Lacy, MPH, 434-243-0126, rmc9p@virginia.edu
Charles Landen, MD, 434-924-9333, CL3NJ@hscmail.mcc.virginia.edu
About this study
The purpose of this project is to establish a bank at UVa of tampon samples, cervical swabs, blood, associated tumor specimens that would otherwise be discarded, and relevant medical data from consenting patients that have suspected and/or confirmed gynecological cancer diagnoses. The specimens collected will be saved for analysis on future projects to determine if factors in the specimens are predictive and/or correlated to gynecological cancer diagnoses and/or outcomes
Read the detailed description
The purpose of this project is to establish a bank at UVa of tampon samples, cervical swabs, blood, associated tumor specimens that would otherwise be discarded, and relevant medical data from consenting patients that have suspected and/or confirmed gynecological cancer diagnoses. The specimens collected will be saved for analysis on future projects to determine if factors in the specimens are predictive and/or correlated to gynecological cancer diagnoses and/or outcomes. The bank will contain: 1) 10cc of blood drawn through venipuncture annually; 2) tampons placed in the patients vagina prior to surgery or clinic visit; 3) swabs of the endocervical canal; 4) freshly collected leftover and to-be-discarded tumors from ovarian, uterine, cervical, as well as leftover normal tissue, and ascites fluid, from samples collected for diagnostic purposes. These samples and patient-associated medical record data will be banked and used for future research and analyses. Samples will be saved in multiple formats for later tumor profiling (i.e. FFPE, snap frozen, in RNA-later, etc). These samples and information will be used to determine the underlying causes of cancers and chemoresistance, so that better methods of treatment, management, and prevention of gynecological cancers may be discovered in the future.
Samples will be linked and coded, with all HIPAA protected information removed, for storage and sharing with other investigators to protect patient information. Only coded samples and clinical information will be used in this protocol for when samples, information, and/or data are shared with other investigators at UVa or outside institutions in the future. A separate password protected/encrypted file will contain the patient identifiers and the key to the coded sample numbers. This file will only be accessible by the PI or study team listed on this protocol on UVa premises, and will only be stored on a UVa server behind the UVa firewall, and will not be stored or accessed on personal computers. Thus, identified patient information will not be accessible to any individual, except the PI or study team listed on this protocol, ensuring protection of patient information. In addition, coded patient samples and medical data from specimens obtained from the University of Alabama-Birmingham, that were previously collected by the PI under local IRB approval (IRB-HSR #18042), have been transferred to UVA under a fully executed MTA, and will be assimilated into this databank at UVa for future research.
- Conditions
- Ovarian Cancer
- Being tested
- Tampons
- Keywords
- tampons; ovarian cancer
- Medical subject headings
- Ovarian Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
TamponsOther
Collection of tampons, blood, cervical swabs, tissue and ascites
| Study group | Role | What they receive |
|---|---|---|
| Surgical or High Risk | Patients with confirmed diagnosis of ovarian cancer or suspicious mass or who have a family history or genetic mutation that puts them at high risk fro ovarian cancer. Receives: Other: Tampons |
What is being measured
The primary outcome is the main question the study is designed to answer.
To establish a bank of specimens at UVa
banking specimens for future testing
Measured: 10 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Nov 2019
- Study start10 Jun 2016
- Primary completion10 Jun 2022 (estimated)
- Study completion10 Jun 2022 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Ovarian CancerStudies of the same condition, open and under way.
- More trials run by University of VirginiaThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 400 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Virginia
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Charles Landen, MD, Principal investigator, University of Virginia
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04170712
- Sponsor's protocol ID
- 18620
- Status last verified
- Apr 2020
- First submitted
- 17 Nov 2019
- Last updated
- 20 Apr 2020
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 20 Apr 2020. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Data and Specimen Bank of Patients Diagnosed With, and at High-risk for, Gynecologic Cancers
- ClinicalTrials.gov ID
- NCT04170712
- Acronym / sponsor ID
- 18620
- Conditions
- Ovarian Cancer
- Keywords
- tampons; ovarian cancer
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 400 participants (estimated)
- Lead sponsor
- University of VirginiaUniversity, hospital or other
- Study start
- 10 Jun 2016 (actual)
- Primary completion
- 10 Jun 2022 (estimated)
- Study completion
- 10 Jun 2022 (estimated)
- First posted
- 20 Nov 2019 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this project is to establish a bank at UVa of tampon samples, cervical swabs, blood, associated tumor specimens that would otherwise be discarded, and relevant medical data from consenting patients that have suspected and/or confirmed gynecological cancer diagnoses. The specimens collected will be saved for analysis on future projects to determine if factors in the specimens are predictive and/or correlated to gynecological cancer diagnoses and/or outcomes
Detailed description
The purpose of this project is to establish a bank at UVa of tampon samples, cervical swabs, blood, associated tumor specimens that would otherwise be discarded, and relevant medical data from consenting patients that have suspected and/or confirmed gynecological cancer diagnoses. The specimens collected will be saved for analysis on future projects to determine if factors in the specimens are predictive and/or correlated to gynecological cancer diagnoses and/or outcomes. The bank will contain: 1) 10cc of blood drawn through venipuncture annually; 2) tampons placed in the patients vagina prior to surgery or clinic visit; 3) swabs of the endocervical canal; 4) freshly collected leftover and to-be-discarded tumors from ovarian, uterine, cervical, as well as leftover normal tissue, and ascites fluid, from samples collected for diagnostic purposes. These samples and patient-associated medical record data will be banked and used for future research and analyses. Samples will be saved in multiple formats for later tumor profiling (i.e. FFPE, snap frozen, in RNA-later, etc). These samples and information will be used to determine the underlying causes of cancers and chemoresistance, so that better methods of treatment, management, and prevention of gynecological cancers may be discovered in the future.
Samples will be linked and coded, with all HIPAA protected information removed, for storage and sharing with other investigators to protect patient information. Only coded samples and clinical information will be used in this protocol for when samples, information, and/or data are shared with other investigators at UVa or outside institutions in the future. A separate password protected/encrypted file will contain the patient identifiers and the key to the coded sample numbers. This file will only be accessible by the PI or study team listed on this protocol on UVa premises, and will only be stored on a UVa server behind the UVa firewall, and will not be stored or accessed on personal computers. Thus, identified patient information will not be accessible to any individual, except the PI or study team listed on this protocol, ensuring protection of patient information. In addition, coded patient samples and medical data from specimens obtained from the University of Alabama-Birmingham, that were previously collected by the PI under local IRB approval (IRB-HSR #18042), have been transferred to UVA under a fully executed MTA, and will be assimilated into this databank at UVa for future research.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Surgical or High Risk | – | Other: TamponsPatients with confirmed diagnosis of ovarian cancer or suspicious mass or who have a family history or genetic mutation that puts them at high risk fro ovarian cancer. |
Who may qualify
- Ages
- 18 years and older
- Sex
- Female only
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- Patients with confirmed ovarian cancer diagnosis or suspicious mass or patients with a strong family history of ovarian cancer or genetic mutation that puts them at high risk for ovarian cancer
Key inclusion criteria (3 listed)
- Adult female non-pregnant patients with high risk for gynecological and/or breast cancer who will be:
Key exclusion criteria (2 listed)
- • Is under the age of 18
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| TamponsCollection of tampons, blood, cervical swabs, tissue and ascites | Other | Surgical or High Risk |
Primary outcome
To establish a bank of specimens at UVa
Time frame: 10 years
banking specimens for future testing
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 20 Apr 2020.
- Individual participant dataSharing planned: No
Related trials for Ovarian Cancer
Recruiting
Methylation Profiling in Self-Samples for Identification of (Epi)Genetic Biomarkers for Gynecological Cancers
Gynaecological Cancers, Ovarian Cancer
Recruiting
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
Ovarian Carcinoma
RecruitingPhase 2
Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
Ovarian Cancer, Fallopian Tube Cancer
Active, not recruitingPhase 1/2
Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can...
Colorectal Neoplasms, Breast Neoplasms
Recruiting
The Vanguard Study: Testing a New Way to Screen for Cancer
Bladder Carcinoma, Breast Carcinoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Charles Landen, MD principal investigator
University of Virginia
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Ovarian Cancer, run by University of Virginia at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 20 Apr 2020. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Rachel M Lacy, MPH (434-243-0126, rmc9p@virginia.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
To establish a bank of specimens at UVa (time frame: 10 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Apr 2020.